Abstract 270P
Background
Premenopausal women experience temporary ovarian function suppression (OFS) during the period of chemotherapy. In ER+ breast cancer, chemotherapy-induced temporary OFS may offer anti-estrogenic effect in addition to direct cytotoxic anti-tumor effect. It is unclear whether anti-estrogenic effect by temporary OFS during neo-adjuvant chemotherapy (NAC) enhance anti-tumor effect. Based on pathologic complete response (pCR) and complete cell-cycle arrest (CCCA), we compared pathologic response and outcomes between younger and older patients with ER+HER2- breast cancer treated with NAC.
Methods
Between 2007 January and 2021 June, we retrospectively identified 1,178 patients with ER+HER2- breast cancer who underwent NAC in the Gangnam Severance Hospital and the Asan Medical Center. We compared the pCR rate according to age under 45 and over 55 and investigated durations of NAC, clinical stage, and Ki-67. Pathologic complete response was defined as no invasive residual disease in both breast and axillae. In addition, we collected available Ki67 expression in surgical specimen after NAC. We defined low Ki67 with a cutoff of 2.7%. The recurrence-free survival was evaluated in patients with post-NAC Ki67.
Results
In all 1,178 patients, the pCR rate was 1.9% (22/1,178). The rate was 1.4% (8/552) in younger patients (age ≤45), whereas it was 3.6% (9/250) in older patients (age ≥55) (p= 0.063, Chi-square test). In 524 patients who received NAC consisting of anthracyclines and taxanes with a duration of NAC longer than 6 months, the pCR rate did not differ between the younger patients and the older (2.1%, 5/243 vs. 2.8%, 3/106; p= 0.703). In patients with post-NAC Ki67, the CCCA rates were 66.2% (307/464) in the younger and 39.8% (86/216) in the older, respectively (p<0.001). Survival analyses showed that, compared to patients with CCCA, those without CCCA experienced a significant decrease in RFS in both younger and older women.
Conclusions
While short-term OFS resulting from NAC led to a higher rate of CCCA in premenopausal women, younger women had notably poorer survival outcomes compared to older women. Among premenopausal women, achieving CCCA was associated with a slight improvement in treatment outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Gangnam Severance Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
283P - Patient profiles treated with extended adjuvant neratinib in the early access registry study: NEAR study
Presenter: Michelino De Laurentiis
Session: Poster session 02
284P - Prognostic and predictive impact of uPA/PAI-1 in early breast cancer
Presenter: Vanessa Wieder
Session: Poster session 02
285P - Treatment patterns and clinical outcomes of germline BRCA mutation (gBRCAm)-associated breast cancer (BC): A matched, case-control study
Presenter: Stefania Morganti
Session: Poster session 02
286P - Prognostic role of HER2 expression in patients with ER-positive/HER2-negative breast cancer: Results from a population-based cancer registry study
Presenter: Antonino Musolino
Session: Poster session 02
287P - Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer
Presenter: Johan Staaf
Session: Poster session 02
288P - Prognostic factors in nonmetastatic HER2 ‘low’ & HER2 ‘negative’ breast cancer: Single institute experience
Presenter: Alper Türkel
Session: Poster session 02
289P - Results of the window-of-opportunity clinical trial D-BIOMARK: Study of biomarkers of the antitumor activity of denosumab and its role as a modulator of the immune response in early breast cancer
Presenter: Andrea Vethencourt
Session: Poster session 02
290P - Metabolomic profiling and response to neoadjuvant therapy (NAT) in early breast cancer (EBC)
Presenter: Alessandra Gennari
Session: Poster session 02
291P - Prognostic implications of HER2 gain in patients with HR+/HER2- breast cancer (BC) and TNBC after neoadjuvant chemotherapy (NAC)
Presenter: Emanuela Ferraro
Session: Poster session 02
292P - Unlocking the potential of circulating miRNAs in predicting response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis
Presenter: Paola Tiberio
Session: Poster session 02